By Dr. Charles Kamen, MD — Board-Certified Neurologist
If you've been researching medical weight loss, you've almost certainly come across two names: semaglutide and tirzepatide. Both belong to a class of medications called GLP-1 receptor agonists, and both have transformed how we approach obesity and metabolic health. But they are not the same drug, and choosing between them is not as simple as picking whichever one your friend lost weight on.
As a board-certified neurologist who prescribes both medications at my practice in Las Vegas, I want to give you the clinical picture — not the marketing version.
Before comparing these two medications, you need to understand what they do in your body.
GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut naturally produces after you eat. GLP-1 does several things simultaneously: it signals your pancreas to release insulin, it slows gastric emptying so food stays in your stomach longer, and — critically — it acts on receptors in your brain that regulate appetite and satiety.
This is where my background in neurology becomes directly relevant. The appetite centers in your hypothalamus are not responding to willpower. They are responding to hormonal signals. When those signals are disrupted — through insulin resistance, chronic inflammation, or metabolic dysfunction — your brain literally receives inaccurate information about how much energy you need. GLP-1 therapy corrects that signaling.
Both semaglutide and tirzepatide work on this pathway. But they do it differently.
Semaglutide (brand names Ozempic for diabetes, Wegovy for weight management) was FDA-approved for chronic weight management in 2021. It is a pure GLP-1 receptor agonist, meaning it mimics the action of your natural GLP-1 hormone.
What the clinical data shows:
The STEP trials — the landmark studies for semaglutide in weight loss — demonstrated an average body weight reduction of approximately 15% over 68 weeks at the highest dose (2.4 mg weekly). Some participants lost significantly more.
Semaglutide is administered as a once-weekly subcutaneous injection. The dose is titrated up gradually over 16-20 weeks to minimize gastrointestinal side effects.
Where semaglutide excels:
Tirzepatide (brand names Mounjaro for diabetes, Zepbound for weight management) received FDA approval for weight management in 2023. What makes it different is that it is not just a GLP-1 receptor agonist — it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors.
This dual mechanism is significant. GIP is another gut hormone involved in metabolic regulation, and activating both pathways simultaneously appears to produce more potent effects on both blood sugar control and weight reduction.
What the clinical data shows:
The SURMOUNT-1 trial demonstrated that tirzepatide at the highest dose (15 mg weekly) produced an average body weight reduction of approximately 22.5% over 72 weeks. That is a meaningful difference compared to semaglutide's 15%.
Where tirzepatide excels:
Let me lay out the practical differences that matter when you're sitting in my office deciding which medication to start.
| Factor | Semaglutide | Tirzepatide |
|--------|-------------|-------------|
| Average weight loss | ~15% body weight | ~22.5% body weight |
| Mechanism | GLP-1 only | GLP-1 + GIP dual agonist |
| Administration | Weekly injection | Weekly injection |
| Titration period | 16-20 weeks | 20+ weeks |
| Long-term safety data | Extensive (5+ years) | Growing (3+ years) |
| Insurance coverage | Broader | Expanding |
| Cost (cash pay) | $400-$600/month | $500-$700/month |
| Common side effects | Nausea, constipation, diarrhea | Nausea, diarrhea, decreased appetite |
This is where I push back against the internet advice telling you to "just get tirzepatide because the numbers are better." Medicine does not work that way.
I often start patients on semaglutide when:
I lean toward tirzepatide when:
But here is the honest truth: individual response varies enormously. I have had patients lose 25% of their body weight on semaglutide and others who responded much better to tirzepatide after a modest response to semaglutide. The clinical trials give us averages. You are not an average.
Both medications share a similar side effect profile because they act on overlapping pathways. The most common side effects are gastrointestinal: nausea, diarrhea, constipation, and decreased appetite (which is partially the point).
These side effects are dose-dependent and typically most pronounced during the titration phase. This is why we increase the dose gradually — your body needs time to adjust. Most patients find that GI symptoms diminish significantly after the first 4-8 weeks at a stable dose.
Serious side effects to be aware of:
I discuss all of these in detail with every patient before starting therapy. If you want a deeper dive, I wrote a complete guide to GLP-1 side effects that covers what to watch for and when to call your doctor.
I know cost is a deciding factor for many patients, so let me be direct.
With insurance coverage, semaglutide currently has broader formulary placement than tirzepatide, though this is changing rapidly. If you have insurance that covers one but not the other, that often makes the decision for you — and that is clinically reasonable, because both are effective medications.
For cash-pay patients, which is common at our Las Vegas practice, both medications are available through compounding pharmacies at significantly lower cost than brand-name formulations. I have a detailed breakdown of insurance versus cash-pay options for weight loss medications if cost is a primary concern.
When a patient comes to me for GLP-1 therapy, I do not start with the prescription pad. I start with a comprehensive metabolic assessment: bloodwork, body composition analysis, medical history review, and an honest conversation about goals and expectations.
From a neurological perspective, I also evaluate factors that most weight loss clinics overlook — sleep quality, stress response, and neurological conditions that can independently affect metabolism and appetite regulation. The brain is the master regulator of body weight. Ignoring it is a mistake.
Based on that assessment, I recommend a specific medication, dose, and monitoring schedule. We check in regularly, adjust as needed, and track objective markers — not just the scale.
If you are in Las Vegas or anywhere in Nevada and considering GLP-1 therapy, I encourage you to schedule a consultation so we can determine which approach makes the most clinical sense for your situation.
Semaglutide and tirzepatide are both remarkable medications that have genuinely changed the landscape of weight management. Neither is universally "better." The right choice depends on your metabolic profile, your goals, your medical history, and how your body responds.
What matters most is working with a physician who understands the mechanisms, monitors your progress, and adjusts your treatment plan based on your individual response — not someone who writes a prescription after a five-minute telehealth visit.
That is the standard of care you deserve, and it is the standard I hold at LiveWell21.
Dr. Charles Kamen is a board-certified neurologist and the founder of LiveWell21, a peptide therapy and metabolic health practice based in Las Vegas, Nevada. He earned his MD from Albert Einstein College of Medicine, completed his internship at Yale-New Haven Hospital, and his neurology residency at Loma Linda University.